A prospective, non-randomized, dual arm, 2:1 ratio, frequency matched trial to evaluate the effect of PREVAIL(Trademark) System vs. REALIZE (Registered Trademark) Adjustable Gastric Band-C System on the percent excess weight loss at 2 years in morbidly obese patients.

Vibrynt, Inc.0 个研究点目标入组 543 人开始时间: 2012年7月4日最近更新: 2020年1月13日

适应症

试验速览

阶段: 未知
状态: 尚未招募
发起方: Vibrynt, Inc.
入组人数: 543

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Non-randomised trial
主要目的: Treatment
盲法: Open (masking not used)

入排标准

年龄范围: 18 Years 至 65 Years（—）
性别: All

入选标准

•Body Mass Index (BMI) greater than or equal to 40 kg/m2 and less than or equal to 50 kg/m2, or greater than or equal to 35 kg/m2 and less than 40 kg/m2 with one or more significant medical conditions related to obesity (comorbid conditions of Type 2 diabetes, dyslipidemia, hypertension, osteoarthritis, obstructive sleep apnea, coronary heart disease, and gallbladder disease)
•5 year history of morbid obesity
•Documented failure with non-surgical, weight-reduction alternatives, such as supervised diet, exercise and behavior modification programs
•Able to comprehend, follow, and give signed informed consent
•Willing to commit to significant lifestyle changes that include diet, eating, and exercise habits for the duration of the clinical trial
•Able to commit to long-term follow-up up to 5 years after device implantation, including implant adjustment visits
•An absence of significant psychopathology that could have limited the participant’s ability to understand the procedure, comply with medical, surgical, and/or behavioral recommendations, as documented during screening assessment
•Family or other strong social support network in place
•Able to commit to the financial requirements of the $2000 study copayment.
•Living within a one hour commute to clinical site (needed for follow up visits)
•Participant’s ability to understand and describe the actions, eating behaviors and lifestyle that resulted in their current weight and are accountable for or have contributed to their current health
•Agree to refrain, for five years following implant placement, from any type of cosmetic or reconstructive surgery (such as abdominal lipoplasty or liposuction, mammoplasty, or removal of excess skin) that will affect body weight
•Agree to refrain from taking any weight loss medications for the five year duration of the study
•Women of childbearing potential agree to practice an effective method of birth control for the five year duration of the study
•Type 2 diabetes mellitus participants that are well-controlled (limited to approximately 30 participants)

排除标准

•History of deep vein thrombosis (DVT) or other known hypercoagulability condition within the previous year
•Exhibits psychological, emotional, or behavioral characteristics which, in the opinion of the investigator, makes the participant a poor candidate for Paragastric Implant or Gastric Band surgery
•Current diagnosis of severe depression
•Documented history of drug and/or alcohol abuse within two years prior to the Screening Visit
•Women of childbearing potential who are not practicing an effective method of birth control or who are pregnant or lactating, or planning to become pregnant within 5 years
•Previous open abdominal surgery, or any other previous surgical procedure, or an abdominal trauma such as a car accident or fall that could interfere with placement of the Vibrynt Implant
•Presence of an umbilical hernia that is irreducible, symptomatic, or greater than 2 cm
•Acute or chronic infection (localized or systemic)
•Current diagnosis of cancer, renal failure, heart failure, or has a terminal illness with life expectancy < 5 years
•Presence of any of the following medical conditions:
•Inflammatory diseases of the gastrointestinal (GI) tract, including severe intractable esophagitis, gastric ulceration, duodenal ulceration, or specific inflammation such as Crohn’s disease or ulcerative colitis that has been active within the past 10 years. Mild gastritis or mild gastric erosion may be treated and the participant included at the discretion of the Site Principal Investigator.
•Congenital or acquired anomalies of the GI tract, including atresias or stenosis
•Hepatomegaly, splenomegaly, or other organomegaly that interferes with implant placement
•Severe cardiopulmonary disease (including heart failure), renal disease or other serious organic disease that may make the participant a poor surgical candidate
•Uncontrolled hypertension in spite of therapy
•Portal hypertension
•Uncontrolled diabetes mellitus in spite of therapy
•Chronic or acute upper GI bleeding conditions, e.g., gastric or esophageal varices
•Cirrhosis of the liver
•Chronic pancreatitis
•Esophageal or gastric disorders including severe preoperative reflux, achalasia, dysmotility, dysphagia, or Barrett’s esophagus
•Presence of a hiatal hernia > 2 cm (0.78 in). Hernias under this size may be repaired at the surgeon’s discretion prior to the implantation procedure per standard of care
•Immunocompromised such as that resulting from chronic oral steroid use, chemotherapeutic agents, or immune deficiency disorders
•Conditions that, in the opinion of the investigator, present an unreasonable risk to the participant. Note that certain conditions may only be noted intraoperatively (e.g., significant adhesions, hiatal hernia). If the condition is found intraoperatively, the participant shall be considered a surgical screen failure.
•Use of prescription or over-the-counter weight reduction medictions or supplements within one month prior to the Screening Visit and for the five year duration of the study.
•Known or suspected allergy to silicone or other materials contained in the Paragastric Implant and Injection Port
•History of intolerance of implanted devices
•Not ambulatory
•History of chronic pain
•Participation in another clinical trial within 8 weeks of the Screening Visit and for the duration of this trial.
•Affiliated with the study site personnel (e.g., the investigators, sub-investigators or study coordinators) or their relatives.
•Candidates excluded from under

研究者

发起方

Vibrynt, Inc.

相似试验

进行中（未招募）

3 期

The use of rituximab in the treatment of nephrotic glomerulonephritis (TURING)

ISRCTN16948923Cambridge University Hospitals NHS Foundation Trust112

进行中（未招募）

1 期

The Use of Rituximab IN treatment of immune-mediated Glomerulonephritis (TURING)Minimal Change Disease (MCD) and Focal segmental glomerulosclerosis (FSGS)

EUCTR2018-004611-50-GBCambridge University Hospitals NHS Foundation Trust112

已完成

3 期

A clinical study to compare the immunogenicity and safety of Inactivated Influenza vaccine (split virion) I.P. (Tetravalent) 0.5ml in healthy children aged 6 to 35 months

CTRI/2022/05/042514Cadila Healthcare Limited346

进行中（未招募）

2 期

A clinical study to evaluate immune response and safety of Hepatitis E Vaccine in healthy subjects

CTRI/2023/02/049637Zydus Lifesciences Limited

已完成

3 期

A clinical trial to study the effects of two drugs, Dynapar QPS and placebo topical solution in patient suffering from osteoarthritis.

CTRI/2015/02/005510Troikaa Pharmaceuticals Limited212